FL-AMGTA
17.11.2020 14:01:06 CET | Business Wire | Press release
The Additive Manufacturer Green Trade Association (AMGTA), a global trade group created to foster and promote the environmental benefits of additive manufacturing (AM), announced today the publication of its first commissioned university research project, a literature-based systematic review of the environmental benefits of metal AM. The paper, titled, “State of Knowledge on the Environmental Impacts of Metal Additive Manufacturing” was written by Dr. Jeremy Faludi from Delft University of Technology and Corrie Van Sice from Dartmouth College.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201117005440/en/
Key takeaways from the report include that, while “AM generally has much higher carbon footprints per kg of material processed than CM [conventional manufacturing] when considering the direct manufacturing process itself”, but “impacts depend greatly on part geometry—a solid cube will be much lower impact to produce by machining, while a hollow shell or lattice can be lower impact to produce by AM.” The report further recognizes the need for additional life cycle assessment (LCA) studies to quantify environmental impacts: “More LCA studies are necessary to definitively compare metal AM to CM; especially direct comparisons of AM to machining, and especially for technologies such as binder jetting and DED. These LCAs should ideally also include more of the product life cycle.”
“We were pleased to work with Dr. Faludi and Ms. Van Sice on this study,” said Sherry Handel, the Executive Director of the AMGTA. “No one should expect metal AM to be a more sustainable way to manufacture basic metal parts given the focused energy inherent in laser melting, but AM should present a more sustainable course for manufacturing finished precision components.” Ms. Handel continued, “These findings validate the AMGTA’s plans to provide the industry with rigorous, independent, and ongoing research. The AMGTA will continue to commission studies and publish research findings in an effort to update the industry and other key stakeholders on what our eco-footprint is now and what we will need to focus on in the future to be more sustainable.”
About the Researchers
Jeremy Faludi, Ph.D., a leading sustainable engineering researcher, was selected by the AMGTA to oversee this project. Dr. Faludi is assistant professor of design engineering at Delft University of Technology, where he specializes in sustainable design methods and green 3D printing, and adjunct faculty of engineering at the Thayer School of Engineering at Dartmouth College. Dr. Faludi earned a Ph.D. in Mechanical Engineering at University of California Berkeley, a Master of Engineering in Product Design at Stanford University, and a B.A. in Physics from Reed College.
Corrie Van Sice was a senior research engineer at the Faludi Lab at the Thayer School of Engineering, Dartmouth College. Ms. Van Sice managed the Green 3D Printing Lab and assessed AM techniques to define best practices for sustainability in the industry. Before joining the Faludi Lab, she was the lead Materials and Processes R&D Engineer at MakerBot Industries in Brooklyn, NY where she developed and scaled print material manufacturing. Ms. Van Sice earned a Master of Professional Studies from the Interactive Telecommunications Program at New York University in 2011.
About AMGTA
The AMGTA was launched in November 2019 to promote the environmental benefits of additive manufacturing (AM) over traditional methods of manufacturing. The AMGTA is a non-commercial, unaffiliated organization open to any additive manufacturer or industry stakeholder that meets certain criteria relating to sustainability of production or process.
Founding Members of the AMGTA include Sintavia, LLC , a leading additive manufacturer focused on the aerospace, defense, and space industry; Taiyo Nippon Sanso Corporation (one of the operating companies under Nippon Sanso Holdings Corporation), a supplier of stable industrial gases to a wide variety of global industries; and QC Laboratories, Inc. , an industrial and commercial non-destructive testing laboratory focused on AM components.
Participating Members of the AMGTA include AMEXCI AB , Danish AM Hub , EOS , GE Additive , Materialise , National Manufacturing Institute Scotland , Siemens Digital Industries Software , SLM Solutions Inc. , and Stryker .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201117005440/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
